(Q35667007)

9 August 2017

1 reference

title

Strategies for converting allergens into hypoallergenic vaccine candidates (English)

1 reference

9 August 2017

5

Rudolf Valenta

1 reference

9 August 2017

Susanne Vrtala

1

1 reference

9 August 2017

Margarete Focke-Tejkl

series ordinal

2

1 reference

9 August 2017

Ines Swoboda

series ordinal

3

1 reference

9 August 2017

Dietrich Kraft

series ordinal

4

1 reference

9 August 2017

publication date

1 March 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

32

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

313-320

1 reference

Biology and genetics of atopic disease

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Signalling through the high-affinity IgE receptor Fc epsilonRI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Signal transduction by Fc receptors: the Fc epsilon RI case

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Immunologic changes associated with allergen immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

The future of antigen-specific immunotherapy of allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Allergen source materials and quality control of allergenic extracts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Specific immunotherapy - the induction of new IgE-specificities?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Recombinant allergens for diagnosis and therapy of allergic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

7 January 2021

Recombinant allergens

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Immunological and structural similarities among allergens: prerequisite for a specific and component-based therapy of allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Quantitative IgE inhibition experiments with purified recombinant allergens indicate pollen-derived allergens as the sensitizing agents responsible for many forms of plant food allergy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Identification of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Type 1 allergic reactions to plant-derived food: a consequence of primary sensitization to pollen allergens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

IgE to Bet v 1 and profilin: cross-reactivity patterns and clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

T cell clones specific for Bet v I, the major birch pollen allergen, crossreact with the major allergens of hazel, Cor a I, and alder, Aln g I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Cross-reactivity of IgE antibodies with allergens in birch pollen, fruits and vegetables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Identification of Profilin as a Novel Pollen Allergen; IgE Autoreactivity in Sensitized Individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Immunotherapy with partially purified and standardized tree pollen extracts. II. Results of skin prick tests and nasal provocation tests from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Effects of birch pollen-specific immunotherapy on apple allergy in birch pollen-hypersensitive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Recombinant allergens for immunoblot diagnosis of tree-pollen allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Diagnosis of grass pollen allergy with recombinant timothy grass (Phleum pratense) pollen allergens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Recombinant allergen fragments as candidate preparations for allergen immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Hyposensitization to allergic reaction in rDer f 2-sensitized mice by the intranasal administration of a mutant of rDer f 2, C8/119S.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Oral administration of a dominant T-cell determinant peptide inhibits allergen-specific TH1 and TH2 cell responses in Cry j 2-primed mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Antigen-specific T cell tolerance down-regulates mast cell responses in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Studies on allergoids from naturally occurring allergens III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Immunological properties of conjugates of ragweed pollen antigen E with methoxypolyethylene glycol or a copolymer of D-glutamic acid and D-lysine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Immunostimulatory DNA sequences necessary for effective intradermal gene immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1 and to recombinant Bet v 1 wild type in skin chamber fluids collected from birch pollen–allergic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Treatment of cat allergy with T-cell reactive peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

The safety and efficacy of ALLERVAX CAT in cat allergic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2003.08.016

10.1016/J.YMETH.2003.08.016

7 January 2021

Identifiers

DOI

1 reference

9 August 2017

1 reference